XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.4
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2022 $ 5,848 $ 232,508,484 $ (129,688,467) $ 102,825,865 $ 600,380 $ 103,426,245
Balance (in Shares) at Sep. 30, 2022   5,848,504          
Issuance of common stock for services $ 4 101,996 102,000 102,000
Issuance of common stock for services (in Shares)   4,000          
Issuance of common stock upon exercise of stock options $ 2 31,265 31,267 31,267
Issuance of common stock upon exercise of stock options (in Shares)   1,867          
Issuance of common stock in registered direct offering, net of costs $ 500 13,797,683 13,798,183 13,798,183
Issuance of common stock in registered direct offering, net of costs (in Shares)   500,000          
Stock-based compensation expense 6,616,705 6,616,705 6,616,705
Net loss (32,542,912) (32,542,912) (32,542,912)
Balance at Sep. 30, 2023 $ 6,354 253,056,133 (162,231,379) 90,831,108 600,380 91,431,488
Balance (in Shares) at Sep. 30, 2023   6,354,371          
Issuance of common stock for services $ 15 284,161 284,176 284,176
Issuance of common stock for services (in Shares)   15,479          
Issuance of common stock upon exercise of stock options $ 2 (2)
Issuance of common stock upon exercise of stock options (in Shares)   2,082         2,125
Issuance of common stock offerings, net of costs $ 876 13,802,808 13,803,684 $ 13,803,684
Issuance of common stock offerings, net of costs (in Shares)   875,311          
Stock-based compensation expense 11,839,678 11,839,678 11,839,678
Merger, net of transaction costs of $2,358,780 (3,831,357) (3,831,357) (3,831,357)
Minority interest from Merger (3,711,000) (3,711,000) 3,711,000
Net loss (39,425,839) (39,425,839) (39,425,839)
Net loss attributable to noncontrolling interest 287,000 287,000 (287,000)
Balance at Sep. 30, 2024 $ 7,247 $ 271,440,421 $ (201,370,218) $ 70,077,450 $ 4,024,380 $ 74,101,830
Balance (in Shares) at Sep. 30, 2024   7,247,243